

**SERUM LEVEL OF FETUIN-A IN SYSTEMIC
LUPUS ERYTHEMATOSUS (SLE) : RELATION TO
DISEASE ACTIVITY AND ACCELERATED
ATHEROSCLEROSIS**

Thesis

Submitted to the Medical Research Institute
University of Alexandria
In partial fulfillment of the
Requirements of the degree of

Master In Applied Medical Chemistry

By

Osama Fathy Abd El-Wahab Mohamed Mosa

B.Sc. of Biochemistry/Chemistry – Alexandria University

**Medical Research Institute
Alexandria University – Egypt
2009**

SUPERVISORS

Prof. Dr. Mona Mohamed Rashad

Professor of Applied Medical Chemistry
Medical Research Institute
Alexandria University

Prof. Dr. Eman Abd El-Moneim Sharaf

Professor of Biochemistry
Medical Research Institute
Alexandria University

Prof. Dr. Eman Salah Eldin Khalil

Assist Prof. of Internal Medicine
Medical Research Institute
Alexandria University

مستوي الفتيون-أ في مصل الدم في مرضي الذئبة الحمراء و علاقته
بالنشاط المرضي و تصلب الشرايين المتسرع

رسالة

مقدمة لمعهد البحوث الطبية -جامعة الإسكندرية
إيفاءً جزئياً لشروط- الحصول علي درجة

ماجستير في الكيمياء الطبية التطبيقية من

أسامه فتحي عبد الوهاب محمد

بكالوريوس كيمياء حيوية و كيمياء
كلية العلوم- جامعة الإسكندرية

قسم الكيمياء الطبية التطبيقية
معهد البحوث الطبية- جامعة الإسكندرية

٢٠٠٩

المشرفون

أ.د/ مني محمد رشاد

أستاذ الكيمياء الطبية التطبيقية

قسم الكيمياء الطبية التطبيقية

معهد البحوث الطبية- جامعة الإسكندرية

أ.د/ إيمان عبد المنعم شرف

أستاذ الكيمياء الحيوية


قسم الكيمياء الحيوية

معهد البحوث الطبية- جامعة الإسكندرية

د/ إيمان صلاح الدين خليل

أستاذ مساعد أمراض الباطنة

معهد البحوث الطبية- جامعة الإسكندرية



Dedicated To

**My Father
My Mother**

My Wife,

**My Son &
My Sister**

ACKNOWLEDGEMENT

First of all, I wish to express my deepest gratitude and thanks to Allah, whose magnificent help was the main factor in accomplishing this work .

I would like to express my sincere thanks and gratitude to **Prof. Dr. Mona Mohamed Rashad** Professor of Applied Medical Chemistry, Medical Research Institute Alexandria for their endless advice and support throughout the investigation of this thesis.

It is with great pleasure that I record my deepest gratitude and special appreciation to **Prof. Dr. Eman Abd El-moneim Sharaf** Professor of Biochemistry, Medical Research Institute, Alexandria University for suggesting the point of the research, indispensable advice, supervision and support during this work .

Deep thanks to **Prof. Dr. Eman Salah Eldin Khalil**, Assistant Professor of Internal Medicine, Medical Research Institute, Alexandria University for suggesting the point of this thesis, Supervision and unlimited patience, which enabled me to carry out this research their encouragement .

I wish to express thanks to the head and staff members of Applied Medical Chemistry, Biochemistry, Kidney Unit, Medical Research Institute, Alexandria University for their kind help and cooperation .

TABLE OF CONTENTS

Chapter	Page
ACKNOWLEDGEMENT.....	I
TABLE OF CONTENTS.....	II
LIST OF TABLES.....	III
LIST OF FIGURES.....	IV
LIST OF ABBREVIATIONS.....	V
I. INTRODUCTION.....	1
II. AIM OF THE WORK.....	12
III. SUBJECTS AND METHODS.....	13
IV. RESULTS.....	30
V. DISCUSSION.....	72
VI. SUMMARY AND CONCLUSION.....	79
VII. REFERENCES.....	81
PROTOCOL	
ARABIC SUMMARY	

LIST OF ABBREVIATIONS

ASVD	: Atherosclerotic vascular disease .
AHSG	: Alpha 2-Heremans-Schimd glycoprotein .
Bcl-2	: B-cell leukemia/lymphoma 2 .
BRC	: bromocriptine .
BVSMC	: Bovine vascular smooth muscle cells .
CTLA4	: Cytotoxic T-lymphocyte-associated protein 4.
CaMKIV	: Ca ²⁺ -calmodulin kinase IV.
CVD	: Coronary vascular disease.
CVC	: Cardiovascular calcification .
DHT	: Dihydrotestosterone .
DHEA	: Dehydroepiandrosterone .
DNA	: Deoxy ribonucleic acid .
Fcγ Rs	: Fc gamma receptors .
GnRH hormone	: Gonadotropin-releasing
HD	: Hemodialysis .
HLA	: Human leukocyte antigen .
HPA	: Hypothalamic-pituitary adrenal axis .
HPG	: Hypothalamic-pituitary gonadal axis .
IL-2	: Interleukin -2 .
INF-γ	: Interferon gamma .
IMT .	: Intimal media thickness
MHC I	: Major histocompatibility complex I .
MHC II	: Major histocompatibility complex II .
MBL	: Mannose-binding lectin .
NSAID	: Non-steroidal anti-inflammatory drugs
OxLDL	: Oxidized low density lipoprotein .
PBMC	: Peripheral blood mononuclear cell .
PRL	: Prolactin .
SLE	: Systemic lupus erythematosus .
SLEDAI	: Systemic lupus erythematosus activity index .
TNF factor	: Tumor necrosis
TNFRs	: Tumor necrosis factor receptors .
Th1	: T-helper cell type 1 .
Th2	: T-helper cell type 2 .
TGF-β	: Transforming growth factor- beta .
UV	: Ultraviolet .
VSMC	: Vascular smooth muscle cells .
ANA	: Anti-nuclear antibody .

List of Figures

	Page
Figure(1): Different pathophysiological mechanisms and clinical aspects characterizing SLE and probably other autoimmune disorders ⁽³¹⁾ .	6
Figure(2):- Schematic representation of the atherogenic effects of a systemic inflammatory state.	7
Figure (3): Standard curve of serum Fetuin-A (g/l).	19
Figure (4): Standard curve of calcium (mg/dL).	20
Figure (5): Standard curve of serum C3 Complement.	24
Figure (6) : Intima Media Thickness (mm) in normal control and SLE patient groups.	33
Figure (7) : Serum fetuin-A levels (g/l) in normal control and SLE patient groups	35
Figure (8) : Serum calcium levels (mg/dl) in normal control and SLE patient groups.	37
Figure (9): Serum phosphate levels (mg/dl) in normal control and SLE patient groups.	39
Figure (10): Calcium × Phosphate (Ca× P) product levels (mg ² /dl ²) in normal control and SLE patient groups .	41
Figure (11): Calcification Risk Index (CRI) in normal control and SLE patient groups	43
Figure (12): Serum C3 complement levels (g/l) in normal control and SLE patient groups.	45
Figure (13): Serum total cholesterol levels (mg/dl) in normal control and SLE patient groups.	47
Figure(14): Serum triglycerides levels (mg/dl) in normal control and SLE patient groups.	49
Figure(15): Serum HDL-Cholesterol (HDL-C) levels (mg/dl) in normal control and SLE patient groups.	51
Figure(16): Serum VLDL-Cholesterol (VLDL-C) levels (mg/dl) in normal control and SLE patient groups.	53
Figure (17): Serum LDL-Cholesterol (LDL-C) levels (mg/dl) in normal control and SLE patient groups.	55
Figure(18): Serum creatinine levels (mg/dl) in normal control and SLE patient groups.	57
Figure (19): Serum Urea levels (mg/dl) in normal control and SLE patient groups.	59
Figure (20): Correlation between IMT (mm) and SLEDAI in SLE patient group.	61
Figure (21): Correlation between IMT (mm) and C3 complement (g/l) in SLE patient group .	61
Figure (22): Correlation between Age and Fetuin-A (g/l) in SLE patient group.	62
Figure (23): Correlation between IMT (mm) and Fetuin-A (g/l) in SLE patient group.	62
Figure (24) : Correlation between Fetuin-A (g/l) and SLEDAI in SLE patient group.	63
Figure (25): Correlation between Fetuin-A (g/l) and CRI in SLE patient group.	63
Figure (26): Correlation between Fetuin-A (g/l) and Calcium × Phosphate (Ca × P) product (mg ² /dl ²) in SLE patient group.	64
Figure(27): Correlation between C3 complement (g/l) and SLEDAI in SLE patient group.	64
Figure (28): Correlation between C3 complement(g/l)and Fetuin-A (g/l) in SLE patient group.	65

Figure (29): Correlation between C3 complement (g/l) and Triglycerides (mg/dl) in SLE patient group.	65
Figure (30): Correlation between C3 complement (g/l) and Total Cholesterol (mg/dl) in SLE patient group.	66
Figure (31): Correlation between C3 complement (g/l) and LDL (mg/dl) in SLE patient group .	66
Figure (32): Correlation between C3 complement (g/l) and VLDL (mg/dl) in SLE patient group.	67
Figure (33) : Correlation between Fetuin-A (g/l) and Triglycerides (mg/dl) in SLE patient group.	67
Figure(34): Correlation between Fetuin-A (g/l)and LDL (mg/dl) in SLE patient group.	68
Figure (35): Correlation between Fetuin-A (g/l) and VLDL (mg/dl) in SLE patient group.	68
Figure (36): Correlation between SLEDAI and Triglycerides (mg/dl) in SLE patient group.	69
Figure (37): Correlation between SLEDAI and VLDL (mg/dl) in SLE patient group.	69
Figure (38): Correlation between SLEDAI and Total Cholesterol (mg/dl) in SLE patient group.	70
Figure (39): Correlation between SLEDAI and LDL (mg/dl) in SLE patient group.	70

List of Tables

	Page
Table (I): Criteria for classification of Systemic Lupus erythematosus.	2
Table(II): Clinical features in systemic lupus erythematosus and their approximate cumulative prevalence (ACP).	3
Table (III) : Summary of drug induced lupus.	9
Table(IV): Systemic lupus erythematosus activity index (SLEDAI) to assess lupus activity.	15
Table (V): Age distribution of patients with systemic lupus erythematosus (SLE)	30
Table(VI): Systemic Lupus Erythematosus Disease Activity Index Score (SLEDAI)	31
Table (VII) : Intima Media Thickness (IMT) in normal control and SLE patients	32
Table (VIII): Serum values of fetuin-A level (g/l) in normal control and SLE patient groups.	34
Table (IX): Serum values of calcium levels (mg/dl) in normal control and SLE patient groups.	36
Table (X): Serum values of phosphate levels (mg/dl) in normal control and SLE patient groups .	38
Table(XI): Calcium × Phosphate (Ca×P) product levels (mg ² /dl ²) in normal control and SLE patient groups .	40
Table (XII) : Calcification Risk Index (CRI) in normal control and SLE patient groups.	42
Table(XIII): Serum C3 complement levels (g/l) in normal control and SLE patient groups .	44
Table (XIV): Serum total cholesterol levels (mg/dl) in normal control and SLE patient groups	46
Table (XV): Serum triglycerides levels (mg/dl) in normal control and SLE patient groups .	48
Table (XVI): Serum HDL-Cholesterol levels(mg/dl) in normal control and SLE patient groups .	50
Table (XVII): Serum VLDL-Cholesterol levels(mg/dl) in normal control and SLE patient groups	52
Table (XVIII): Serum LDL-Cholesterol levels (mg/dl) in normal control and SLE patient groups	54
Table(XIX): Serum creatinine levels (mg/dl) in normal control and SLE patient groups	56
Table (XX) : Serum urea levels (mg/dl) in normal control and SLE patient groups	58
Table (XXI): Mean values of different biochemical studied parameters in control and SLE patient groups .	60
Table (XXII): Correlation analysis between different studied parameters in control group.	71

INTRODUCTION

History of Systemic lupus erythematosus

The history of lupus can be divided into three periods: the classical period which shows the description of the cutaneous disorder, the neoclassical period which shows the description of the systemic or disseminated manifestations of lupus and the modern period which was heralded by the discovery of the lupus erythematosus (LE) cell.⁽¹⁾

The history of lupus during the classical period was reviewed by Smith and Cyr in 1988.⁽²⁾ The derivation of term lupus and clinical descriptions of cutaneous lesions of lupus vulgaris, lupus profundus, discoid lupus and photosensitive nature of malar or butterfly rash.⁽²⁾

The Neoclassical era of the history of lupus began in 1872 when Kaposi ⁽³⁾, first described the systemic nature of the disorder. The sentinel event in the mid 1900s, which heralded the modern era was the discovery of LE cell by Hargraves and colleagues in 1948.⁽⁴⁾ The investigators observed these cells in the bone marrow of patients with acute disseminated lupus erythematosus. This discovery ushered in the present era of the application of immunology to the study of lupus erythematosus.⁽⁴⁾

Since 1954, various unusual proteins (antibodies) that act against the patients' own tissues have been found to be associated with systemic lupus erythematosus (SLE). Detection of these abnormal proteins has been used to develop more sensitive tests for SLE like anti-nuclear antibody (ANA), anti-DNA antibody and anti-smith antibody. The presence of these antibodies may be the result of factors other than SLE.⁽⁵⁾

Systemic lupus erythematosus

SLE is an autoimmune disease in which immune system attacks the body cells and tissues, resulting in inflammation and tissue damage. SLE can affect any part of the body, but often harms the heart, joints, skin, kidney, lungs, blood vessels and central nervous system.⁽⁶⁾

SLE reflects a general defect in immune regulation that results in hyperactive T cells and B cells. The role of vascular injury in the pathogenesis of SLE is due to circulating immune complexes of autoantibodies and self antigens are deposited in the vascular wall of SLE patients and activate the complement pathway that initiate inflammatory response.⁽⁷⁾

It is also a disease of unknown cause that may cause variable combinations of fever, rash, hair loss, arthritis, pleuritis, pericarditis, nephritis, anemia, leukopenia, thrombocytopenia and central nervous system diseases. The clinical course of SLE is characterized by periods of remissions and acute or chronic relapses.⁽⁸⁾

Epidemiology

The reported prevalence of SLE in the population is 40 to 150 cases per 100,000 due to improved detection of mild disease, the incidence has nearly tripled in the last 40 years.⁽⁹⁾ Estimated incidence rates in North America, South America, Europe and Asia range from about 15 to 254 per 100,000 per year.⁽¹⁰⁾ In the United

States, data from two states with large urban and minority populations, the prevalence was 104 to 170 per 100,000 women, with prevalence in Afro- American women 2.5 to three-fold higher than in Caucasian women.⁽¹¹⁾

SLE is up to 10 times more common in women than men and typically has a predilection for women in their childbearing years.⁽¹²⁾

The prevalence of SLE is higher among Asians, Afro-Americans, Afro-Caribbeans and Hispanic Americans compared to Americans of European descent in the United States and among Asian Indians compared to Caucasians in Great Britain but is seen infrequently in Blacks in Africa.⁽¹³⁾

Sixty-five percent of patients with SLE have disease onset between the ages of 16 and 55. The remaining 20 percent present before age 16 and 15 percent after age 55. Median ages at diagnosis for white females range from 37 to 50 years, in white males from 50 to 59, in black females from 15 to 44 and in black males from 45 to 64.⁽¹⁴⁾

Diagnostic criteria

The diagnosis of SLE is facilitated by determining whether the patient has 4 of 11 clinical and/or laboratory criteria developed for the classification of SLE (Table I).^(15,16)

Table (I): Criteria for classification of Systemic Lupus erythematosus.^(15,16)

Criterion	Definition / Example
1- Malar rash	Fixed erythema over the malar eminences / tending to spare the nasolabial folds.
2- Discoid rash	Erythematous raised patches and may scar.
3- Photosensitivity	Skin rash as result of unusual reaction to sunlight.
4- Oral ulcer	Usually painless.
5- Arthritis	Non-erosive : Jaccoud's arthropathy.
6- serositis	a) Pleuroitis (Pleuritic pain, Pleural rub, Pleural effusion). b) Pericarditis (ECG changes, Rub, Pericardial effusion).
7- Renal disorder	a) Proteinuria (> 3 + or 0.5 g / day). b) Cellular casts in urine.
8- Neurological disorders	a) seizures. b) Psychosis.
9- Haematological disorders	a) Haemolytic anemia. b) Leukopenia. c) lymphopenia. d) Thrombocytopenia.
10- Immunological	a) Anti-DNA antibodies. b) Anti-sm antibodies. c) Anti-phospholipid antibodies.
11- Anti-nuclear antibody (ANA)	Exclude drug causes.